The San Antonio Breast Cancer Symposium (SABCS) is arguably the most important annual breast cancer convention in the world. For 35 years SABCS has been a focal point for announcements and conversations between some of the leading breast cancer advocates, practitioners and researchers in the world. More than 7,000 individuals register from more than 100 countries to learn and share information about breast cancer, which includes chemotherapy, hormonal therapies and targeted therapies for early-stage and metastatic disease, amongst others.

Breastlink at the 2012 SABCS

The physicians of Breastlink have attended the San Antonio Breast Cancer Symposium for more than 15 years. For 2012 we are going to be trying something new – sharing our observations and thoughts from the symposium as events unfold on our Facebook, Twitter, Google + and right here on our blog. We are excited to share that six members of our team will be attending this year:

  • Dr. James Waisman (breast medical oncologist).
  • Dr. Janet Ihde (surgical oncologist).
  • Dr. Nimmi Kapoor (breast and thyroid surgical oncologist).
  • Kristi Maya, Breastlink director of oncology services and the Breastlink Research Group’s research director.
  • Barbara Stankova, manager of research development for the Breastlink Research Group.

Announcements from Past San Antonio Breast Cancer Symposiums

Data that will be released at the 2012 SABCS is under embargo until the start of its presentation time or an official press conference. The first press conference will be held on Wednesday. Some of the major developments from past symposiums include:

SABCS 2011 Highlights

  • Studies showing unprecedented benefits with a pertuzumab-based regimen in metastatic breast cancer in the CLEOPATRA trial.
  • Two studies demonstrating long-term benefits of zoledronic acid in patients with early stage breast cancer.

SABCS 2010 Highlights

  • Research announcements suggesting cellular selection during xenograft formation is similar to that during metastases.
  • Different tumor types (estrogen receptor (ER) – positive, HER2-positive, triple negative) may share some mutational hot spots. These mutations are known to be relatively common and susceptible to drug therapy regimens.
  • Evidence that breast cancer stem cells appear to be ER-negative – even when the primary tumor is ER-positive.

SABCS 2009 Highlights

  • Studies identifying four new PI3K/PTEN pathway activators and inhibitors. This has implications in the development of new treatment options for metastatic patients.
  • News from the complete sequencing of a metastatic ER-positive lobular breast cancer.
  • Results for a BIG-198 trial showed first-line letrozole is superior to tamoxifen. This implies a strong trend towards survival benefit for patients with early stage breast cancer.